Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track OCUL with free AI briefings, catalyst countdowns, and dilution alerts.

OCUL · Ocular Therapeutix, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$530.6M Cash on Hand
24mo Cash Runway
15.6% Short Interest
$25.73 Analyst Target (11)
Follow OCUL by email Get an email when OCUL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about OCUL, unsubscribe in one click. Privacy

📣 What OCUL Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Cyclosporine 0.1% Ophthalmic Solution Dry Eye Disease (DED) N/A · NCT07904728 Recruiting
Tyrvaya Dry Eye N/A · NCT07705893 Recruiting
Topical prednisolone acetate Cataract Phase 4 · NCT05023304 Completed
Intravitreal injection of axitinib hydrogel… Non-Proliferative Diabetic Retinopathy Phase 3 · NCT07235085 Recruiting
OTX-TKI Neovascular Age-related Macular Degeneration Phase 3 · NCT06495918 Active not recruiting
Single intravitreal injection of axitinib… Non-Proliferative Diabetic Retinopathy Phase 3 · NCT07235085 Recruiting
OTX-TIC high dose Travoprost Intracameral… Open Angle Glaucoma Phase 2 · NCT05335122 Completed

Also used in these trials (approved or third-party drugs, not OCUL's own candidates): Dexamethasone, Lifitegrast, Prednisolone Acetate, Aflibercept, Bimatoprost.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

OCUL holds $530.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $66.4M/quarter from operations, an estimated runway of 24 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 13 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when OCUL files for a raise →

👥 Who Owns OCUL

Insiders 2.8% Institutions (348 holders) 95.8% Public and other holders 1.4%
HolderTypeShares% of sharesAs of
FMR, LLC Institution (13F) 33,160,034 15.07% 2026-09-30
Deep Track Capital, LP Institution (13G, 5%+) 20,850,000 9.48% 2026-03-31
BlackRock, Inc. Institution (13G, 5%+) 15,227,768 6.92% 2026-06-30
Avoro Capital Advisors LLC Institution (13F) 12,380,300 5.63% 2026-09-30
SUMMER ROAD LLC Institution (13G, 5%+) 12,134,357 5.52% 2025-12-04
Venrock Adviser, LLC Institution (13F) 10,346,926 4.70% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 8,941,052 4.06% 2026-09-30
Price (T.Rowe) Associates Inc Institution (13F) 7,190,029 3.27% 2026-09-30
Logos Global Management LP Institution (13F) 6,000,000 2.73% 2026-09-30
State Street Corporation Institution (13F) 5,575,452 2.53% 2026-09-30
Geode Capital Management, LLC Institution (13F) 5,273,141 2.40% 2026-09-30
Pravin Dugel
Executive Chairman, President and CEO, D
Insider 3,270,332 1.49% 2026-08-24

Share count 220,022,840 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-06
filed 2026-11-10
Sherif Riad
Award (A) 28,000 – 28,000
2026-11-06
filed 2026-11-10
Sherif Riad
Option award (A) 88,000 – –
2026-11-05
filed 2026-11-09
Saroj Namrata
Sale (S) 35,370 $6.55 220,522
2026-10-08
filed 2026-10-13
Anderman Todd
Sale (S) 11,984 $7.29 140,484
2026-10-02
filed 2026-10-06
Kaiser Peter
Sale (S) 9,990 $7.05 254,388

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full OCUL picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OCUL and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.